Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lanconone
- Development stage
- Unknown
- Lead developer
- Enovate Biolife
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Lanconone (E-OA-07) is a standardized botanical dietary supplement developed by Enovate Biolife for the management of chronic joint pain and osteoarthritis. The formulation is a unique combination of extracts from seven Ayurvedic herbs: *Commiphora mukul*, *Boswellia serrata*, *Withania somnifera*, *Oroxylum indicum*, *Smilax china*, *Pluchea lanceolata*, and *Zingiber officinale*. It acts as a multi-target anti-inflammatory agent, inhibiting key mediators of joint degradation and pain, including cyclooxygenase-2 (COX-2), 5-lipoxygenase (5-LOX), tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1beta). Clinical studies have demonstrated that Lanconone significantly reduces pain and stiffness while improving physical function in patients with knee osteoarthritis, often showing a rapid onset of action and a favorable safety profile compared to conventional non-steroidal anti-inflammatory drugs (NSAIDs).
- Brand names
- Lanconone
- Other names
- E-OA-07E-OA07E-OA 07
02
Targets
ALOX12 (Arachidonate 12-lipoxygenase, 12S type)COX
Beyond the preview
Go deeper on Lanconone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lanconone.